Pharma bets on agentic AI
What happened
- Major drugmakers are embedding agentic AI across R&D, manufacturing, supply chains and commercial operations. - Merck signed a $1 billion Google Cloud deal to deploy agentic AI enterprise‑wide. - Novo Nordisk is also partnering with OpenAI while continuing clinical programs like its oral GLP‑1 trial in youths. (merck.com)(reuters.com)
Why it matters
Drugmakers are moving from testing artificial intelligence to wiring it into daily operations, with Merck putting up to $1 billion behind that shift. (merck.com) Merck and Google Cloud said on April 22 that the multiyear deal will deploy an “agentic” platform across research and development, manufacturing, commercial and corporate work. Merck said the program will use Gemini Enterprise and Google Cloud engineers alongside Merck teams. (merck.com) In plain terms, agentic AI means software that does multi-step work with less hand-holding than a chatbot: pulling data, drafting outputs, routing tasks and triggering follow-up actions. Merck said it plans to use that setup for end-to-end research workflows, predictive manufacturing and more personalized commercial and patient engagement. (merck.com) The push reaches beyond one company. Novo Nordisk said on April 14 that it had partnered with OpenAI to change how medicines are discovered and delivered, adding another large drugmaker to the list of companies tying core operations to generative AI systems. (novonordisk.com) (openai.com) That comes as pharma companies keep using AI first on work that is easier to measure than inventing a new drug from scratch. Reuters reported in January that companies were already using AI to find trial sites and patients and to draft regulatory documents, cutting time from labor-heavy tasks. (kelo.com) Merck framed the latest deal as part of a wider rebuild of its digital backbone for 75,000 employees worldwide. The company said it has used data science, artificial intelligence and machine learning in discovery and development for more than a decade, but the new agreement expands that work across the enterprise. (merck.com 1) (merck.com 2) Novo Nordisk is making the same bet while still leaning on traditional clinical development. On April 23, the company said oral semaglutide met the main goal in a late-stage trial in 132 patients ages 10 to 17 with type 2 diabetes over 26 weeks. (newsbreak.com) (clinicaltrials.gov) OpenAI has also been building products aimed at health systems and regulated users. In January, it launched OpenAI for Healthcare, saying the offering supports HIPAA compliance requirements and gives organizations secure controls for clinical, research and operational work. (openai.com) The immediate test for these pharma deals is not whether an AI model discovers a blockbuster molecule next month. It is whether companies can make research, factories, supply chains and sales operations move faster without creating errors that regulated drugmakers cannot afford. (merck.com) (kelo.com)
Key numbers
- Merck signed a $1 billion Google Cloud deal to deploy agentic AI enterprise‑wide.
- Novo Nordisk is also partnering with OpenAI while continuing clinical programs like its oral GLP‑1 trial in youths.
- (merck.com)(reuters.com) Drugmakers are moving from testing artificial intelligence to wiring it into daily operations, with Merck putting up to $1 billion behind that shift.
- (merck.com) Merck and Google Cloud said on April 22 that the multiyear deal will deploy an “agentic” platform across research and development, manufacturing, commercial and corporate work.
What happens next
- (merck.com) Merck and Google Cloud said on April 22 that the multiyear deal will deploy an “agentic” platform across research and development, manufacturing, commercial and corporate work.
- Merck said the program will use Gemini Enterprise and Google Cloud engineers alongside Merck teams.
- Merck said it plans to use that setup for end-to-end research workflows, predictive manufacturing and more personalized commercial and patient engagement.
Quick answers
What happened in Pharma bets on agentic AI?
Major drugmakers are embedding agentic AI across R&D, manufacturing, supply chains and commercial operations. Merck signed a $1 billion Google Cloud deal to deploy agentic AI enterprise‑wide. Novo Nordisk is also partnering with OpenAI while continuing clinical programs like its oral GLP‑1 trial in youths. (merck.com)(reuters.com)
Why does Pharma bets on agentic AI matter?
Drugmakers are moving from testing artificial intelligence to wiring it into daily operations, with Merck putting up to $1 billion behind that shift. (merck.com) Merck and Google Cloud said on April 22 that the multiyear deal will deploy an “agentic” platform across research and development, manufacturing, commercial and corporate work. Merck said the program will use Gemini Enterprise and Google Cloud engineers alongside Merck teams. (merck.com) In plain terms, agentic AI means software that does multi-step work with less hand-holding than a chatbot: pulling data, drafting outputs, routing tasks and triggering follow-up actions. Merck said it plans to use that setup for end-to-end research workflows, predictive manufacturing and more personalized commercial and patient engagement. (merck.com) The push reaches beyond one company. Novo Nordisk said on April 14 that it had partnered with OpenAI to change how medicines are discovered and delivered, adding another large drugmaker to the list of companies tying core operations to generative AI systems. (novonordisk.com) (openai.com) That comes as pharma companies keep using AI first on work that is easier to measure than inventing a new drug from scratch. Reuters reported in January that companies were already using AI to find trial sites and patients and to draft regulatory documents, cutting time from labor-heavy tasks. (kelo.com) Merck framed the latest deal as part of a wider rebuild of its digital backbone for 75,000 employees worldwide. The company said it has used data science, artificial intelligence and machine learning in discovery and development for more than a decade, but the new agreement expands that work across the enterprise. (merck.com 1) (merck.com 2) Novo Nordisk is making the same bet while still leaning on traditional clinical development. On April 23, the company said oral semaglutide met the main goal in a late-stage trial in 132 patients ages 10 to 17 with type 2 diabetes over 26 weeks. (newsbreak.com) (clinicaltrials.gov) OpenAI has also been building products aimed at health systems and regulated users. In January, it launched OpenAI for Healthcare, saying the offering supports HIPAA compliance requirements and gives organizations secure controls for clinical, research and operational work. (openai.com) The immediate test for these pharma deals is not whether an AI model discovers a blockbuster molecule next month. It is whether companies can make research, factories, supply chains and sales operations move faster without creating errors that regulated drugmakers cannot afford. (merck.com) (kelo.com)
